Shots:

• Kite enters into a two-year research collaboration and license agreement with HiFiBiO to discover novel targets and Abs against AML
• HiFiBiO will receive an up front and will utilize its technology platform to identify novel AML targets and anti-AML specific Abs to support Kite’s development of cell therapies
• Kite to get an exclusive option to opt-in any targets emerges during the collaboration- for which HiFiBiO will receive an additional payment and is eligible to receive development- regulatory and commercial milestones along with royalties on sales of Abs

­ Ref: Gilead | Image: Technology Networks